House & Home
Tue, May 12, 2009Mon, May 11, 2009Fri, May 8, 2009Thu, May 7, 2009Fri, May 1, 2009Thu, April 16, 2009Wed, April 15, 2009Tue, April 14, 2009Mon, April 13, 2009Thu, April 9, 2009Wed, April 8, 2009Tue, April 7, 2009Mon, April 6, 2009Fri, April 3, 2009Thu, April 2, 2009Wed, April 1, 2009Tue, March 31, 2009Mon, March 30, 2009Fri, March 27, 2009Thu, March 26, 2009Wed, March 25, 2009Tue, March 24, 2009Mon, March 23, 2009Fri, March 20, 2009Thu, March 19, 2009Wed, March 18, 2009Tue, March 17, 2009Mon, March 16, 2009Fri, March 13, 2009Thu, March 12, 2009Wed, March 11, 2009Tue, March 10, 2009Mon, March 9, 2009Fri, March 6, 2009Thu, March 5, 2009Wed, March 4, 2009Tue, March 3, 2009Mon, March 2, 2009Fri, February 27, 2009Thu, February 26, 2009Wed, February 25, 2009Tue, February 24, 2009Mon, February 23, 2009Fri, February 20, 2009Thu, February 19, 2009Wed, February 18, 2009Tue, February 17, 2009Mon, February 16, 2009Paladin Labs Inc. Paladin Files New Drug Submissionfor TRELSTAR R 6 Month
//house-home.news-articles.net/content/2009/03/0 .. s-new-drug-submissionfor-trelstar-r-6-month.html
Published in House and Home on Monday, March 9th 2009 at 6:03 GMT, Last Modified on 2009-03-09 06:03:45 by Market Wire🞛 This publication is a summary or evaluation of another publication
MONTREAL, CANADA--(Marketwire - March 9, 2009) - Paladin Labs Inc. (TSX:PLB), a leading Canadian specialty pharmaceutical company, announced today that it has filed a new drug submission for TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension). Trelstar® 22.5 mg is a 6-month slow release, injectable, luteinizing hormone-releasing hormone (LHRH) agonist indicated for the palliative treatment of advanced prostate cancer.
"Trelstar® is an important component of Paladin's urology franchise and this new dosage form will further strengthen this portfolio," said Jonathan Ross Goodman, President and CEO of Paladin Labs.
Paladin obtained the Canadian license for TRELSTAR® from Watson Pharma Inc., a subsidiary of Watson Pharmaceuticals, Inc. (NYSE:WPI) in May 2005. Paladin launched TRELSTAR® 11.25 mg 3 month for the treatment of advanced prostrate cancer in August 2006 and launched TRELSTAR® 3.75 mg 1 month for the treatment of advanced prostate cancer and endometriosis in January 2007.
According to IMS Canada, the total Canadian market for LHRH agonists in 2008 is $141.5 million, up 3% from 2007.
About Paladin Labs Inc.
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products. With this strategy, a focused Canadian national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. For more information, please visit the Company's web site at [ www.paladinlabs.com ].
These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Companies consider the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but caution that these assumptions regarding the future events, many of which are beyond the control of the Companies and their subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual reports, as well as in the Companies' Annual Information Forms for the year ended December 31, 2007. The Companies disclaim any intention or obligation to update or revise any forward-looking statements whether a result of new information, future events, or except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Companies' ongoing quarterly filings, annual reports and Annual Information Forms and other filings found on SEDAR at [ www.sedar.com ].